PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32187752-7	2020	Currently, the most promising potential drug candidate to slow AAA growth is metformin, and RCTs to verify or reject this hypothesis are warranted.	Metformin	77-86	AAA1	Homo sapiens	63-66	
30936409-1	2019	OBJECTIVE: To assess the association of metformin prescription with the risk of aortic aneurysm, aortic aneurysm events and the enlargement of abdominal aortic aneurysm (AAA).	Metformin	40-49	AAA1	Homo sapiens	170-173	
30936409-9	2019	We found that metformin prescription could significantly limit the enlargement of aortic aneurysm (weighted mean difference: -0.83 mm/year, 95% CI -1.38 to -0.28, I2=89.6%) among patients with AAA.	Metformin	14-23	AAA1	Homo sapiens	193-196	
30936409-11	2019	CONCLUSIONS: According to the available epidemiological evidence, metformin prescription could limit the expansion of AAA among patients with this disease, and may be involved with a lower incidence of aortic aneurysm and aortic aneurysm events.	Metformin	66-75	AAA1	Homo sapiens	118-121	
30936409-12	2019	Randomised controlled trials are needed to confirm whether metformin could reduce the enlargement of AAA in patients with or without diabetes.	Metformin	59-68	AAA1	Homo sapiens	101-104